Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
Want to see MAZE full AI Analyst Report?
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:47Neutral
Price Target:
$27.00
▼(-3.88% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by weak financial performance (large losses and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a strengthened runway from the $150M financing and a currently manageable leverage profile, but valuation is constrained by negative earnings and no dividend support.
Positive Factors
Extended cash runway
The combined cash, proceeds from the April registered offering and milestone receipts provide a multi-year runway into 2029, materially lowering near-term financing pressure. This durability allows clinical programs to advance to pivotal stages without immediate capital raises, reducing execution risk.
Negative Factors
Sustained cash burn
Persistent large negative operating and free cash flows indicate the company remains consumption-driven by R&D and trial costs. Continued burn increases reliance on capital markets or partners to fund development if trial timelines extend, creating recurrent dilution and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway
The combined cash, proceeds from the April registered offering and milestone receipts provide a multi-year runway into 2029, materially lowering near-term financing pressure. This durability allows clinical programs to advance to pivotal stages without immediate capital raises, reducing execution risk.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.39B
Dividend YieldN/A
Average Volume (3M)748.57K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees125
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume492,222
30 Day Avg. Volume748,567
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue64.38
Enterprise Value/Gross Profit69.95
Enterprise Value/Ebitda-10.20
Forecast
1Y Price Target
$63.50Price Target Upside126.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$12.50M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes M...
How the Company Makes Money
null...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | 18.41M | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -126.22M | -140.50M | 60.88M | -94.46M | -107.21M |
| Net Income | -122.54M | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | |||||
| Total Assets | 419.71M | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 352.38M | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 61.22M | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 78.01M | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 341.70M | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | |||||
| Free Cash Flow | -122.13M | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -121.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -164.39M | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 190.32M | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $622.12M | 3.50 | 50.38% | ― | 384.60% | 883.51% | |
60 Neutral | $1.75B | -5.01 | 442.91% | ― | 107.73% | 82.33% | |
56 Neutral | $1.43B | -47.34 | -1057.44% | ― | ― | -13.14% | |
52 Neutral | $1.57B | 69.02 | -44.10% | ― | 1205.52% | 81.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.39B | -16.61 | -36.63% | ― | ― | ― | |
47 Neutral | $808.32M | -68.46 | -28.90% | ― | 68.64% | 50.57% |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
25.75
15.47
150.49%
CRMD
Cormedix
8.06
-4.30
-34.79%
GERN
Geron
1.26
-0.19
-13.10%
KALV
KalVista Pharmaceuticals
26.77
15.30
133.39%
ANAB
AnaptysBio
60.41
46.79
343.41%
NUVB
Nuvation Bio
4.79
2.49
108.26%
Maze Therapeutics, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Maze Therapeutics prices $150 million equity offering
Positive
Apr 22, 2026
On April 21, 2026, Maze Therapeutics, Inc. priced an underwritten registered offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants for 850,000 shares at $23.499, for expected gross proceeds of $150 million and es...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Maze Therapeutics adds Neil Kumar to board leadership
Positive
Mar 25, 2026
Maze Therapeutics reported fourth-quarter and full-year 2025 results on March 25, 2026, alongside positive Phase 2 HORIZON topline data for MZE829 showing clinically meaningful reductions in proteinuria in APOL1-mediated kidney disease, and confir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.